ReviewInternational journal of experimental pathology2002
Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway.
Review in International journal of experimental pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Trial
- mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.Nature immunology · 2026Article
- Virulence Mechanisms ofFrontiers in microbiology · 2022Review
- Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease.Journal of inflammation research · 2022Article
- Beyond Antibiotics: Photo/Sonodynamic Approaches for Bacterial Theranostics.Nano-micro letters · 2020Review
- A novel ATM mutation associated with elevated atypical lymphocyte populations, hyper-IgM, and cutaneous granulomas.Clinical immunology (Orlando, Fla.) · 2019Article
- Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models.Antimicrobial agents and chemotherapy · 2015Article
- Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen.PLoS neglected tropical diseases · 2014Article
- Intact IFN-γR1 expression and function distinguishes Langerhans cell histiocytosis from mendelian susceptibility to mycobacterial disease.Journal of clinical immunology · 2014Review
- Etiology of sarcoidosis: does infection play a role?The Yale journal of biology and medicine · 2012Review
- The blessings and curses of intestinal inflammation.Cell host & microbe · 2010Review
- CCL5 participates in early protection against Mycobacterium tuberculosis.Journal of leukocyte biology · 2010Article
- Gamma-delta T cell subsets are differentially associated with granuloma development and organization in a bovine model of mycobacterial disease.International journal of experimental pathology · 2009Article
- Hypercholesterolemia impairs immunity to tuberculosis.Infection and immunity · 2008Article
- Live Mycobacterium avium subsp. paratuberculosis and a killed-bacterium vaccine induce distinct subcutaneous granulomas, with unique cellular and cytokine profiles.Clinical and vaccine immunology : CVI · 2008Article
- Tuberculosis susceptibility of diabetic mice.American journal of respiratory cell and molecular biology · 2007Article
- Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.European journal of immunology · 2007Article
- Whipple's disease: a macrophage disease.Clinical and vaccine immunology : CVI · 2006Review
- Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection.Clinical and experimental immunology · 2006Article
- Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis.Infection and immunity · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with genetic lesions in the Type-1 cytokine/cytokine receptor pathway exhibit a selective susceptibility to severe infections with poorly pathogenic mycobacteria and non-typhi salmonella spp. These experiments of nature demonstrate that IL-12-dependent IFNgamma production is critical for granuloma formation and therefore host immunity against such pathogens. The essential role of granuloma formation for protective immunity to these organisms is emphasized by the differing granuloma forming capabilities and resultant clinical sequelae observed in these patients which seems to reflect their ability to produce or respond to IFNgamma (Fig. 9). At one pole of this spectrum, represented by the complete IFNgammaR1/2 deficient patients, there is a complete absence of mature granuloma formation, whereas with the less severe mutations (i.e. partial IFNgammaR1/2, complete IL-12p40 and complete IL-12Rbeta1 deficiency), granuloma formation is very heterogenous with wide variations in composition being observed. This suggests that in the latter individuals, who produce partial but suboptimal IFNgamma responses, other influences, including pathogen virulence and host genotype may also affect the type and scale of the cellular response elicited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.